Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Operating Margin (2018 - 2025)

Lipocine's Operating Margin history spans 8 years, with the latest figure at 2933.51% for Q3 2025.

  • For Q3 2025, Operating Margin changed N/A year-over-year to 2933.51%; the TTM value through Sep 2025 reached 119.21%, down 24208.0%, while the annual FY2024 figure was 0.02%, 12047.0% up from the prior year.
  • Operating Margin reached 2933.51% in Q3 2025 per LPCN's latest filing, down from 386.03% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 5207.01% in Q2 2021 to a low of 7889.86% in Q1 2023.
  • Average Operating Margin over 5 years is 1433.8%, with a median of 545.77% recorded in 2025.
  • Peak YoY movement for Operating Margin: tumbled -591251bps in 2022, then soared 793216bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 59.09% in 2021, then plummeted by -1294bps to 705.51% in 2022, then crashed by -680bps to 5506.19% in 2023, then skyrocketed by 101bps to 77.4% in 2024, then plummeted by -3890bps to 2933.51% in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Operating Margin are 2933.51% (Q3 2025), 386.03% (Q2 2025), and 2226.82% (Q1 2025).